CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,208 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01077258
NCT01077258N/ACompleted
CompareCT.gov

Effectiveness and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

AbbVie (prior sponsor, Abbott)·observational·Posted Mar 1, 2010·Updated Apr 25, 2014

In Brief

An observational study for Rheumatoid Arthritis. Completed, enrolled 4,208 participants across 303 sites.

Detailed Summary

Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over 2 years.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 1, 2010
Enrollment StartApr 1, 2004
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 16.3 years ago